{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:37:31Z","timestamp":1792121851443,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":41,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.rpth.2024.102476","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:11:20Z","timestamp":1718669480000},"page":"102476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1989-959X","authenticated-orcid":false,"given":"Huyen","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"von Mackensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aby","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kingsley","family":"Hampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Knoebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Linari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Odgaard-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper Skov","family":"Neergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksandra","family":"Stasyshyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay Jay","family":"Thaung Zaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Zulfikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102476_bib1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.rpth.2024.102476_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2516.2008.01709.x","article-title":"Quality of life in haemophilia","volume":"14","author":"Gringeri","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102476_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102476_bib4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1016\/j.rpth.2024.102476_bib5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/hae.12642","article-title":"Interpreting important health-related quality of life change using the Haem-A-QoL","volume":"21","author":"Wyrwich","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102476_bib6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2516.2009.02112.x","article-title":"Development and validation of a new questionnaire for the assessment of subjective physical performance in adult patients with haemophilia \u2013 the HEP-Test-Q","volume":"16","author":"von Mackensen","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102476_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2516.2004.01016.x","article-title":"Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List","volume":"10","author":"van Genderen","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102476_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s41687-019-0158-6","article-title":"The expansion and validation of a new upper extremity item bank for the Patient-Reported Outcomes Measurement Information System(R) (PROMIS)","volume":"3","author":"Kaat","year":"2019","journal-title":"J\u00a0Patient Rep Outcomes"},{"key":"10.1016\/j.rpth.2024.102476_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2516.2009.02129.x","article-title":"VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia","volume":"16","author":"Duncan","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102476_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41687-023-00550-6","article-title":"Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM)","volume":"7","author":"Brod","year":"2023","journal-title":"J\u00a0Patient Rep Outcomes"},{"key":"10.1016\/j.rpth.2024.102476_bib11","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/hae.13736","article-title":"The burden of bleeds and other clinical determinants on caregivers of children with haemophilia (the BBC Study)","volume":"25","author":"Khair","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102476_bib12","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s11136-019-02168-y","article-title":"Longitudinal validity of the hemophilia caregiver impact measure","volume":"28","author":"Schwartz","year":"2019","journal-title":"Qual Life Res"},{"key":"10.1016\/j.rpth.2024.102476_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12955-017-0643-7","article-title":"Predictors of quality of life among adolescents and young adults with a bleeding disorder","volume":"15","author":"McLaughlin","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.rpth.2024.102476_bib14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ejh.13108","article-title":"The socioeconomic burden of patients affected by hemophilia with inhibitors","volume":"101","author":"D'Angiolella","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2024.102476_bib15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/hae.13377","article-title":"Impact of pain and functional impairment in US adults with haemophilia: patient-reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P-FiQ) study","volume":"24","author":"Kempton","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102476_bib16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1186\/s13023-021-02152-1","article-title":"Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe","volume":"16","author":"Burke","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.rpth.2024.102476_bib17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13023-018-0929-9","article-title":"Inhibitor clinical burden of disease: a comparative analysis of the CHESS data","volume":"13","author":"Oladapo","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.rpth.2024.102476_bib18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/hae.13731","article-title":"Health-related quality of life and health status in persons with haemophilia A with inhibitors: a prospective, multicentre, non-interventional study (NIS)","volume":"25","author":"Mahlangu","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102476_bib19","first-page":"46","article-title":"Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII\/IX","volume":"6","author":"Rocino","year":"2017","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.rpth.2024.102476_bib20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/hex.13404","article-title":"The lived experience of a novel disruptive therapy in a group of men and boys with haemophilia A with inhibitors: Emi & Me","volume":"25","author":"Fletcher","year":"2022","journal-title":"Health Expect"},{"key":"10.1016\/j.rpth.2024.102476_bib21","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102476_bib22","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/jth.15697","article-title":"Regulation of coagulation by tissue factor pathway inhibitor: implications for hemophilia therapy","volume":"20","author":"Mast","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102476_bib23","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/jth.14272","article-title":"A\u00a0randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A","volume":"16","author":"Eichler","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102476_bib24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102476_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/hae.14099","article-title":"Outcome measures in haemophilia: beyond ABR (annualized bleeding rate)","volume":"27","author":"Manco-Johnson","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102476_bib26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/rth2.12195","article-title":"Hemophilia trials in the twenty-first century: defining patient important outcomes","volume":"3","author":"Konkle","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102476_bib27","series-title":"Handbook of disease burdens and quality of life measures","first-page":"1895","article-title":"Quality of life in hemophilia","author":"von Mackensen","year":"2010"},{"key":"10.1016\/j.rpth.2024.102476_bib28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hae.13140","article-title":"Measurement properties of the Haem-A-QoL in haemophilia clinical trials","volume":"23","author":"von Mackensen","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102476_bib29","article-title":"Treatment experience in hemophilia patients with and without inhibitors on concizumab prophylaxis: Hemo-TEM results from the phase 2 explorer4 & 5 studies [abstract]","volume":"6","author":"Mancuso","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102476_bib30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/hae.13754","article-title":"From the voices of people with haemophilia A and their caregivers: challenges with current treatment, their impact on quality of life and desired improvements in future therapies","volume":"25","author":"Wiley","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102476_bib32","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/hae.14363","article-title":"The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies","volume":"27","author":"Skinner","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102476_bib33","first-page":"29","article-title":"Switching from syringe-to-vial to a prefilled subcutaneous pen injector in haemophilia \u2013 as easy as Abc? [abstract]","volume":"23","author":"M\u00f8ller","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102476_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.101193","article-title":"A\u00a0usability study assessing handling and preference of the concizumab pen-injector in patients with haemophilia and caregivers [abstract]","volume":"7","author":"Rasmussen","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102476_bib35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1586\/erd.12.13","article-title":"FlexTouch(R) for the delivery of insulin: technical attributes and perception among patients and healthcare professionals","volume":"9","author":"Bailey","year":"2012","journal-title":"Expert Rev Med Devices"},{"key":"10.1016\/j.rpth.2024.102476_bib36","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41591-024-02827-9","article-title":"Recommendations to address respondent burden associated with patient-reported outcome assessment","volume":"30","author":"Aiyegbusi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2024.102476_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010938","article-title":"Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review","volume":"6","author":"Mercieca-Bebber","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.rpth.2024.102476_bib38","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/hae.14144","article-title":"Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company","volume":"26","author":"Hay","year":"2020","journal-title":"Haemophilia"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924001651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924001651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T03:16:16Z","timestamp":1728357376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924001651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2475037924001651"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102476","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102476"}}